EirGenix has signed the agreement with TaiMed Biologics to provide development and manufacturing services for TaiMed’s second generation anti-HIV monoclonal antibody, TMB-360.
The scope of this collaboration project includes cell line development, process development and scale-up for manufacturing to provide materials for pre-clinical and clinical studies.
Compared to the first generation anti-HIV mAb, TMB-355, the new generation drug possesses significant improvements in terms of overcoming anti-drug resistance, efficiency and pharmacokinetics;
with these advantages, TMB-360 will become a stronger successor to TMB-355 to benefit patients diagnosed with AIDS.
By utilizing EirGenix’s development platforms and manufacturing services, it is anticipated TMB-360 will reach the market well within the expected schedule.
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity